UroGen's ZUSDURI Shows 64.5% Three-Year Durability in Bladder Cancer Trial
Event summary
- ZUSDURI achieved a 64.5% three-year duration of response in the ENVISION trial, with median duration not yet reached.
- 79.6% of patients achieved a complete response at three months, and 64.5% remained event-free at three years.
- ZUSDURI is the first and only FDA-approved non-surgical treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
- The trial involved 240 patients across 56 sites, with a median follow-up of 35.5 months.
- Adverse reactions were mainly mild to moderate, with serious adverse events occurring in 12% of patients.
The big picture
UroGen's ZUSDURI represents a significant advancement in the treatment of recurrent LG-IR-NMIBC, offering a non-surgical alternative to the current standard of care, TURBT. The durable responses observed in the ENVISION trial highlight the potential for ZUSDURI to reduce the treatment burden for patients and improve quality of life. This development aligns with broader industry trends toward minimally invasive and patient-friendly cancer treatments, particularly for older populations with comorbidities.
What we're watching
- Market Adoption
- Whether ZUSDURI can shift the treatment paradigm for LG-IR-NMIBC away from repeated surgical interventions.
- Regulatory Dynamics
- How the FDA's approval of ZUSDURI will influence the regulatory landscape for non-surgical bladder cancer treatments.
- Commercialization Strategy
- The pace at which UroGen can scale the commercialization of ZUSDURI to address the 59,000 annual recurrent LG-IR-NMIBC cases in the U.S.
Related topics